TRIB (Trinity Biotech) EBIT: $-24.06 Mil (TTM As of Dec. 2025)


TRIB Trinity Biotech PLC TRIB
20 GF Score
Price $0.33
GF Value $0.73
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech EBIT?

Trinity Biotech TRIB -5.69% 20 EBIT is $-24.06 Mil as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 20/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 7 warning signs investors should review.

Trinity Biotech's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-15.85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-24.06 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Trinity Biotech's annualized ROC % for the quarter that ended in Dec. 2025 was -5.82%. Trinity Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -545.63%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Trinity Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -17.25%.

Trinity Biotech  (NAS:TRIB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Trinity Biotech's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-7.368 * ( 1 - 0.44% )/( (71.197 + 180.991)/ 2 )
=-7.3355808/126.094
=-5.82 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=99.631 - 26.958 - ( 1.546 - max(0, 31.523 - 32.999+1.546))
=71.197

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=105.165 - 29.481 - ( 5.138 - max(0, 141.209 - 35.902+5.138))
=180.991

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Trinity Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-31.69/( ( (4.309 + max(2.005, 0)) + (5.302 + max(-0.55199999999998, 0)) )/ 2 )
=-31.69/( ( 6.314 + 5.302 )/ 2 )
=-31.69/5.808
=-545.63 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.893 + 20.129 + 0) - (26.958 + 0 + 2.059)
=2.005

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.362 + 18.828 + 1.654) - (29.481 + 0.187 + 0.72799999999998)
=-0.55199999999998

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Trinity Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-24.063/139.528
=-17.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech EBIT Related Terms

Trinity Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech EBIT Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.52 -32.25 -26.78 -18.77 -24.06

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.31 -4.45 -14.32 -8.22 -15.85

TRIB vs PMI, NXL, CSDX: EBIT Comparison

For the Medical Devices subindustry, Trinity Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's EV-to-EBIT falls into.


TRIB
20GF Score
Trinity Biotech PLC TRIB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trinity Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-24.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-24.06 Mil mean?
Trinity Biotech (TRIB) has a EBIT of $-24.06 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Trinity Biotech.
Is Trinity Biotech's EBIT too high?
Trinity Biotech's current EBIT is $-24.06 Mil. Overall, Trinity Biotech has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's EBIT compare to PMI and NXL?
Trinity Biotech's EBIT of $-24.06 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Trinity Biotech. Trinity Biotech's current EBIT is $-24.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.33 — trading 54.8% below its estimated fair value. The current EBIT is $-24.06 Mil. Trinity Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current EBIT is $-24.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.33 is trading 54.8% below its estimated GF Value™ of $0.73. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • EBIT: $-24.06 Mil
  • GF Value™: $0.73 vs. price of $0.33 (54.8% below fair value)
  • GF Score™: 20/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score

Get the complete analysis for TRIB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.73
GF Value